Cargando…

Pharmacogenetic Testing for Prevention of Severe Cutaneous Adverse Drug Reactions

Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS), are idiosyncratic and unpredictable drug-hypersensitivity reactions with a high-mortality rate ranging from 10% to over...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Chih-Jung, Chen, Chun-Bing, Hung, Shuen-Iu, Ji, Chao, Chung, Wen-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346738/ https://www.ncbi.nlm.nih.gov/pubmed/32714190 http://dx.doi.org/10.3389/fphar.2020.00969

Ejemplares similares

Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation
por: Su, Shih-Chi, et al.
Publicado: (2016)

Current understanding of genetic associations with delayed hypersensitivity reactions induced by antibiotics and anti-osteoporotic drugs
por: Wung, Chih-Hsuan, et al.
Publicado: (2023)

Identification of drug-specific public TCR driving severe cutaneous adverse reactions
por: Pan, Ren-You, et al.
Publicado: (2019)

Digging Up the Human Genome: Current Progress in Deciphering Adverse Drug Reactions
por: Su, Shih-Chi, et al.
Publicado: (2014)

Genetics of Severe Cutaneous Adverse Reactions
por: Yang, Shang-Chen, et al.
Publicado: (2021)

Pharmacogenetics and Predictive Testing of Drug Hypersensitivity Reactions
por: Böhm, Ruwen, et al.
Publicado: (2016)

Role of Pharmacogenetics in Adverse Drug Reactions: An Update towards Personalized Medicine
por: Micaglio, Emanuele, et al.
Publicado: (2021)

An Updated Review of Genetic Associations With Severe Adverse Drug Reactions: Translation and Implementation of Pharmacogenomic Testing in Clinical Practice
por: Wang, Chuang-Wei, et al.
Publicado: (2022)

Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review
por: Chen, Chun-Bing, et al.
Publicado: (2023)

Real-World Efficiency of Pharmacogenetic Screening for Carbamazepine-Induced Severe Cutaneous Adverse Reactions
por: Chen, Zhibin, et al.
Publicado: (2014)

Cytotoxic Proteins and Therapeutic Targets in Severe Cutaneous Adverse Reactions
por: Su, Shih-Chi, et al.
Publicado: (2014)

Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies
por: Chen, Chun-Bing, et al.
Publicado: (2018)

Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies
por: Hung, Shuen-Iu, et al.
Publicado: (2022)

Association between HLA alleles and beta-lactam antibiotics-related severe cutaneous adverse reactions
por: Wattanachai, Pansakon, et al.
Publicado: (2023)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Drug-Induced Severe Cutaneous Adverse Reactions: Insights Into Clinical Presentation, Immunopathogenesis, Diagnostic Methods, Treatment, and Pharmacogenomics
por: Tempark, Therdpong, et al.
Publicado: (2022)

Cutaneous adverse drug reactions induced by Oxcarbazepine
por: Hsiao, Yi-Hsin, et al.
Publicado: (2014)

The pharmacogenomics of carbamazepine-induced cutaneous adverse drug reaction in the South of Vietnam
por: Nguyen, Ai-Hoc, et al.
Publicado: (2023)

Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms
por: Dao, Ro-Lan, et al.
Publicado: (2015)

Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
por: Wu, Angela, et al.
Publicado: (2023)

Use of in vitro tests to assess the causative drugs for NSAIDs-induced type I hypersensitivity
por: Chang, Wan-Chun, et al.
Publicado: (2014)

Pharmacogenetics to Avoid Adverse Drug Reactions
por: López-Fernández, Luis A.
Publicado: (2022)

Therapeutic Drug Monitoring and Pharmacogenetic Testing in Northern China
por: Zhang, Chunyan, et al.
Publicado: (2021)

Genotyping for HLA risk alleles versus patch tests to diagnose anti-seizure medication induced cutaneous adverse drug reactions
por: Manson, Lisanne E. N., et al.
Publicado: (2022)

Pharmacogenetics for severe adverse drug reactions induced by molecular‐targeted therapy
por: Udagawa, Chihiro, et al.
Publicado: (2020)

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland
por: Begré, Ursina B. M., et al.
Publicado: (2022)

Pharmacogenetics of pediatric acute lymphoblastic leukemia in Uruguay: adverse events related to induction phase drugs
por: Burgueño-Rodríguez, Gabriela, et al.
Publicado: (2023)

Usage Pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore Following Implementation of HLA-B*15:02 Genotyping as Standard-of-Care
por: Sung, Cynthia, et al.
Publicado: (2020)

Pharmacogenetics in the Brazilian Population
por: Suarez-Kurtz, Guilherme
Publicado: (2010)

LightSNiP assay is a good strategy for pharmacogenetics test
por: Cheli, Stefania, et al.
Publicado: (2015)

Genetic markers of severe cutaneous adverse reactions
por: Jung, Jae-Woo, et al.
Publicado: (2018)

Risk factors of mortality in severe cutaneous adverse reactions patients with pulmonary involvement
por: Hu, H, et al.
Publicado: (2012)

Delayed Drug Hypersensitivity Reactions: Molecular Recognition, Genetic Susceptibility, and Immune Mediators
por: Chu, Mu-Tzu, et al.
Publicado: (2023)

Treatments for Severe Cutaneous Adverse Reactions
por: Cho, Yung-Tsu, et al.
Publicado: (2017)

Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States
por: Lemke, Lauren K., et al.
Publicado: (2023)

Pharmacogenetics – Challenges and Opportunities Ahead
por: Zanger, Ulrich M.
Publicado: (2010)

Pharmacogenetics in Primary Headache Disorders
por: Belyaeva, Irina I., et al.
Publicado: (2022)

Associations of HLA-A and HLA-B with vancomycin-induced drug reaction with eosinophilia and systemic symptoms in the Han-Chinese population
por: Wang, Chuang-Wei, et al.
Publicado: (2022)

Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations
por: Eum, Seenae, et al.
Publicado: (2016)

HLA-B(*)58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand
por: Sukasem, Chonlaphat, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n835ousckkt9j9lrrj4p8nbmms